Alto Neuroscience(US:ANRO) Globenewswireยท2025-09-19 11:23Core Viewpoint - A class action lawsuit has been filed against Alto Neuroscience, Inc. for allegedly misleading investors regarding the effectiveness of its treatment ALTO-100 for Major Depressive Disorder (MDD) [7]. Allegation Details - The lawsuit claims that the Offering Documents for Alto's IPO were negligently prepared and that the company failed to disclose critical information about ALTO-100's effectiveness [7]. - Specifically, it is alleged that ALTO-100 was less effective in treating MDD than the company had indicated, leading to overstated clinical, regulatory, and commercial prospects [7]. Stock Performance Impact - Following the announcement of the Phase 2b trial results on October 22, 2024, which indicated that ALTO-100 did not meet its primary endpoint, Alto's stock price plummeted by $10.17 per share, a decrease of 69.99%, closing at $4.36 per share on October 23, 2024 [7]. Next Steps for Investors - Investors who purchased Alto securities between February 2, 2024, and October 22, 2024, are encouraged to contact the law firm for more information and to discuss their legal rights [4]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is September 19, 2025 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation [5]. - The firm has offices in New York, California, and South Carolina and specializes in commercial and securities litigation [5].